{"id":48340,"date":"2022-09-14T01:01:44","date_gmt":"2022-09-13T23:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/"},"modified":"2022-09-14T01:01:44","modified_gmt":"2022-09-13T23:01:44","slug":"ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/","title":{"rendered":"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference"},"content":{"rendered":"
\n

\nIn less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q3, 2020 to $987.55 in Q2, 2022<\/i>\n<\/p>\n

\nAHF will host a protest Wednesday, Sept. 14th<\/sup> targeting Gilead Sciences\u2014”Greediad\u201d\u2014and its investors over its AIDS drug pricing during the Baird Global Healthcare Investor Conference at the InterContinental Hotel in New York<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–On Wednesday morning, September 14th<\/sup>, two dozen advocates from AIDS Healthcare Foundation<\/a> (AHF), the largest global AIDS organization, and its affiliates, Iris House and ACQC (AIDS Center of Queens County) will spearhead a protest targeting Gilead Sciences<\/a> (GILD) during the annual Baird Global Healthcare Investor Conference being held at the Intercontinental \u2013 New York Barclay (111 E 48th<\/sup> St) in New York City.\n<\/p>\n

<\/a><\/p>\n

\nGilead officials will be presenting at the conference and the advocates will protest Gilead\u2014\u201cGreediad\u201d\u2014over the drug company\u2019s latest, and illegal move to undermine safety net providers\u2019 access to 340B program benefits. 340B is a drug-company-funded, government administered program that costs taxpayers nothing, and, according to HRSA \u201c\u2026 enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.\u201d<\/i>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nWHAT:\n<\/p>\n<\/td>\n

<\/td>\n\n

\nAIDS Drug Pricing<\/b> PROTEST <\/b>targeting Gilead Sciences, Inc<\/b>.\n<\/p>\n

\nduring the annual Baird Global Healthcare Investor Conference\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWHEN:\n<\/p>\n<\/td>\n

<\/td>\n\n

\nWednesday, September 14th<\/sup>\u20149:40AM \u2013 10:15AM (approx.)<\/i>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWHERE:\n<\/p>\n<\/td>\n

<\/td>\n\n

\nInterContinental \u2013 New York Barclay<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n111 E. 48th<\/sup> Street (between Park & Lexington Aves.), New York, NY 10017\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWHO:\n<\/p>\n<\/td>\n

<\/td>\n\n

\n20+ AIDS drug pricing protesters with \u201cGreediad\u201d and \u201cStop Being Greedy\u201d signs\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nOn-site AHF CONTACT:\n<\/p>\n<\/td>\n

<\/td>\n\n

\nRasheed Gonga<\/b>, (201) 241-0927 cell Rasheed.gonga@ahf.org<\/a>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nIn March<\/a> of this year, Gilead became the 15th drug manufacturer to place unlawful restrictions on 340B contract pharmacy programs. Lawyers for the Health and Human Services Department (HHS) in both the Biden and Trump administrations have said these restrictions are clearly illegal, yet drug companies like Gilead forge ahead with the lawbreaking in search of even greater profits.\n<\/p>\n

\nSince the third quarter of 2020\u2014less than two years\u2014Gilead has also more than doubled<\/a><\/i> the cost of its HIV\/AIDS medication, Descovy, for the 340B program from $445.11 in 2020 to $987.55 in the second quarter of 2022.\n<\/p>\n

\nIn response to Gilead\u2019s (and others\u2019) illegal restrictions on 340B access and its bald-faced greed for higher profits, AHF also asked Congress and the FDA to conduct a formal investigation of Gilead as well as increase scrutiny of the actions of pharmaceutical companies.\n<\/p>\n

\nAIDS Healthcare Foundation<\/b> (AHF), the largest global AIDS organization, currently provides medical care and\/or services to over 1.6 million individuals in 45 countries worldwide in the US, Africa, Latin America\/Caribbean, the Asia\/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org<\/a>, find us on Facebook: www.facebook.com\/aidshealth<\/a>, follow us @aidshealthcare<\/a> or subscribe to our AHF podcast \u201cAHFter Hours.\u201d<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRasheed Gonga<\/b>
Advocacy, Legislative Affairs & Community Engagement for AHF
\n
+1.201.241.0927 mobile
\n
Rasheed.gonga@ahf.org<\/a>\n<\/p>\n

\nImara Canady<\/b>
National Director, Communications & Community Engagement for AHF
\n
+1.770.940.6555 mobile
\n
imara.canady@ahf.org<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

In less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q3, 2020 to $987.55 in Q2, 2022 AHF will host a protest Wednesday, Sept. 14th targeting Gilead Sciences\u2014”Greediad\u201d\u2014and its investors over its AIDS drug pricing during the Baird Global Healthcare … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48340","6":"format-standard","7":"category-industry"},"yoast_head":"\nAHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"In less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q3, 2020 to $987.55 in Q2, 2022 AHF will host a protest Wednesday, Sept. 14th targeting Gilead Sciences\u2014”Greediad\u201d\u2014and its investors over its AIDS drug pricing during the Baird Global Healthcare ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T23:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220913006276\/en\/1570928\/21\/Screen_Shot_2022-09-12.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference\",\"datePublished\":\"2022-09-13T23:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/\"},\"wordCount\":507,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006276\\\/en\\\/1570928\\\/21\\\/Screen_Shot_2022-09-12.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/\",\"name\":\"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006276\\\/en\\\/1570928\\\/21\\\/Screen_Shot_2022-09-12.jpg\",\"datePublished\":\"2022-09-13T23:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006276\\\/en\\\/1570928\\\/21\\\/Screen_Shot_2022-09-12.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006276\\\/en\\\/1570928\\\/21\\\/Screen_Shot_2022-09-12.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference - Pharma Trend","og_description":"In less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q3, 2020 to $987.55 in Q2, 2022 AHF will host a protest Wednesday, Sept. 14th targeting Gilead Sciences\u2014”Greediad\u201d\u2014and its investors over its AIDS drug pricing during the Baird Global Healthcare ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-13T23:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220913006276\/en\/1570928\/21\/Screen_Shot_2022-09-12.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference","datePublished":"2022-09-13T23:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/"},"wordCount":507,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913006276\/en\/1570928\/21\/Screen_Shot_2022-09-12.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/","name":"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913006276\/en\/1570928\/21\/Screen_Shot_2022-09-12.jpg","datePublished":"2022-09-13T23:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220913006276\/en\/1570928\/21\/Screen_Shot_2022-09-12.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220913006276\/en\/1570928\/21\/Screen_Shot_2022-09-12.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ahf-targets-gilead-on-drug-pricing-baird-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AHF Targets Gilead on Drug Pricing @ Baird Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48340"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48340\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}